IP Library › Granted Patent US 12,419,989
Granted Patent B2
US 12,419,989 · App. 18/513,436 · Granted Sep 23, 2025

Solid solution compositions comprising cannabidiols

Inventors: Ethan G. Sherman (Jacksonville, FL); Wei Chen (St. Johns, FL); Denise E. Guenther (Jacksonville, FL)
Assignee: Medtronic Xomed, Inc.
A61L24/0042A61F13/2005A61K9/0043A61L2/0029A61L15/225A61L24/0015A61L24/0036A61L24/043A61L24/08A61L31/042A61L31/146A61L31/148A61L31/16B65B55/16B65B63/08A61L2202/24A61L2300/232A61L2300/404A61L2400/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,419,989
App. No.
18/513,436
Granted
Sep 23, 2025
Kind
B2
Abstract

An implantable article comprising a dissolvable sponge derived from the mixture of chitosan, a first polysaccharide and a second polysaccharides. The polysaccharides have different number average molecular weight characteristics to enable the control of the mechanical features of the sponge.

Claims (21)

1. An article, comprising:

a water-absorbent, porous, dissolvable sponge derived from a mixture of polysaccharides consisting of chitosan and a plurality of cellulosic polysaccharides, and optionally one or more other polysaccharides distinct from chitosan, the plurality of cellulosic polysaccharides having different number average molecular weights enabling control of mechanical features of the dissolvable sponge to form a sponge that is hydratable, has stenting capabilities to hold open an anatomical location, and exhibits a wet or dry compression strength of at least 20 grams according to the Compression Test and a dissolution rate of greater than or equal to 1 day according to the Dissolution Test.

2. The article according to claim 1 , wherein the dissolvable sponge is degradable by mechanical dissolution or chemical dissolution.

3. The article according to claim 1 , wherein the dissolvable sponge when partially hydrated is mucoadhesive and exhibits a mucoadhesive force of 20 grams or greater according to the Adhesive Force Test.

4. The article according to claim 1 , wherein the dissolvable sponge begins to dissolve upon hydration.

5. The article according to claim 1 , wherein the dissolvable sponge exhibits one or more of a wet compression strength or a dry compression strength of at least 100 grams according to the Compression Test, or a dissolution rate of greater than or equal to 1 day according to the Dissolution Test.

6. The article according to claim 1 , wherein the dissolvable sponge when partially hydrated possesses an antibacterial effectiveness from 24 hours to over 14 days with a log reduction of 4 according to the Log Reduction Test.

7. The article according to claim 1 , wherein one or more of the plurality of cellulosic polysaccharides and other polysaccharides include cellulose, agar, alginate, carrageenan, chitin, chondroitin sulfate, dextran, galactomannan, glycogen, hyaluronic acid, starch or a combination thereof.

8. The article according to claim 7 , wherein the cellulose includes hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxymethyl cellulose, or carboxymethyl cellulose.

9. The article according to claim 1 , wherein one or more of the plurality of cellulosic polysaccharides and other polysaccharides include hydroxyethyl cellulose.

10. The article according to claim 1 , wherein the dissolvable sponge is a nasal sponge employed for holding open a nasal passage.

11. The article according to claim 10 , wherein the nasal sponge prevents adhesion of tissue in the sinus cavity.

12. The article according to claim 1 , wherein the chitosan is chitosan hydrochloride.

13. The article according to claim 12 , wherein the dissolvable sponge is antimicrobial.

14. The article according to claim 1 , further comprising an adjuvant selected from the group consisting of non-aqueous solvents, acids, bases, buffering agents, antimicrobial agents and therapeutic agents.

15. The article according to claim 14 , wherein a portion of the therapeutic agent is present in the dissolvable sponge over time until the dissolvable sponge exhibits no compressive strength, as determined in accordance with the Dissolution and Compression Test.

16. The article according to claim 1 , wherein the dissolvable sponge is sterilized by ionizing radiation.

17. The article according to claim 1 , wherein the dissolvable sponge exhibits one or more of a complete hydration in water under 30 seconds, or a fluid absorption of greater than 10 times over its initial dry weight in accordance with the Fluid Absorption Test.

18. The article according to claim 1 , wherein the sponge possesses a pH value in the range of about 4 to about 6.

19. The article according to claim 1 , wherein the dissolvable sponge begins to dissolve upon immersion in an aqueous solution containing saline or phosphate buffered saline.

20. The article according to claim 1 , wherein a hyperosmolar agent is further employed in connection with the dissolvable sponge and is configured to draw water from tissue to change the osmolar content of the mucous layer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2023
From: SHERMAN, ETHAN G; GUENTHER, DENISE E.; CHEN, WEI
To: MEDTRONIC XOMED, INC.
Reel/Frame 065607/0847 →
Continuity (5)
Continuation 17360691 · Jun 28, 2021
Continuation 16706209 · Dec 6, 2019
Continuation 15954471 · Apr 16, 2018
Continuation 14962493 · Dec 8, 2015
Related Publication 20240082456A1 · Mar 14, 2024
References Cited (31)
US 7993675B2 · Oliver et al. · 2011 [cited by applicant]
US 8313762B2 · Oliver et al. · 2012 [cited by applicant]
US 8530632B2 · Tijsma et al. · 2013 [cited by applicant]
US 8668703B2 · Sullivan et al. · 2014 [cited by applicant]
US 8802652B2 · Myntti et al. · 2014 [cited by applicant]
US 8920715B2 · Roberts et al. · 2014 [cited by applicant]
US 9061087B2 · Roberts et al. · 2015 [cited by applicant]
US 9205049B2 · Reddy et al. · 2015 [cited by applicant]
US 9649482B2 · Roberts et al. · 2017 [cited by applicant]
US 10517986B2 · Sherman · 2019 [cited by examiner]
US 11045577B2 · Sherman · 2021 [cited by examiner]
US 11839693B2 · Sherman · 2023 [cited by examiner]
US 20050147658A1 · Tapolsky et al. · 2005 [cited by applicant]
US 20070104769A1 · Feng et al. · 2007 [cited by applicant]
US 20070254016A1 · Andersen et al. · 2007 [cited by applicant]
US 20070264310A1 · Hissong et al. · 2007 [cited by applicant]
US 20090291911A1 · Myntti et al. · 2009 [cited by applicant]
US 20100178313A1 · Larsen et al. · 2010 [cited by applicant]
US 20100239632A1 · Walsh · 2010 [cited by applicant]
US 20110052663A1 · Roberts · 2011 [cited by applicant]
US 20140323433A1 · Myntti et al. · 2014 [cited by applicant]
US 20160184564A1 · Spearman et al. · 2016 [cited by applicant]
US 20170157283A1 · Sherman et al. · 2017 [cited by applicant]
JP 2003159528A · 2003 [cited by applicant]
WO 03020771A1 · 2003 [cited by applicant]
Canadian Examiner's Report for application No. 3,006,565 dated Nov. 17, 2022. [cited by applicant]
Casettari et al., “Chitosan in nasal delivery systems for therapeutic drugs,” <i>Journal of Controlled Release</i>, 190(204): 189-200, Available online May 10, 2014. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2018/064234, dated Jun. 21, 2018 (9 pages). [cited by applicant]
U.S. Appl. No. 14/962,493, filed Dec. 8, 2015, Inventor(s): Sherman et al. [cited by applicant]
501(k) Summary: PosiSep T N' and PosiSep TM X Hemostat Dressing/Intranasal Splint, Hemostasis, LLC, Mar. 27, 2013, 5 pages. [cited by applicant]
Office Action for Japanese Application No. 2018-530136, dated Nov. 24, 2020, 7 pages. [cited by applicant]